Showing 3561-3570 of 3620 results for "".
- Emil Tanghetti, MDhttps://practicaldermatology.com/profiles/emil-tanghetti-md/7N5rqk/He attended U.C Davis where he excelled in his studies and received early admission to UCLA School of Medicine after only three years of undergraduate studies. Upon completing his medical studies and a 1-year pathology fellowship Dr. Tanghetti graduated first in his class and received the Dean Warr…
- David Goldberg, MD, JDhttps://practicaldermatology.com/profiles/david-goldberg-md-jd/OXBNWa/Goldberg earned his medical degree from Yale University. He completed his dermatology residency and dermatologic surgical fellowship at New York University Medical Center. He is a clinical professor and former director of Mohs Surgery and Laser Research in the department of Dermatology at New York’…
- Timothy Wilens, M.D.https://practicaldermatology.com/profiles/timothy-wilens-md/7ZKZJG/Dr. Timothy Wilens is chief of the Division of Child and Adolescent Psychiatry and is co-director of the Center for Addiction Medicine at Massachusetts General Hospital. He is the MGH Trustees Chair in Addiction Medicine and a professor of psychiatry at Harvard Medical School. Dr. Wilens earned hi…
Holding Court in Melanoma: Choosing the Optimal Frontline Treatment Approach for Stage IV BRAF-Wild Type Melanoma
https://practicaldermatology.com/programs/cme/holding-court-in-melanoma-choosing-the-optimal-frontline-treatment-approach-for-stage-iv-braf-wild-type-melanoma/15436/How can we make an informed decision on which target combined with a PD-1 inhibitor provides the most benefit in patients with metastatic melanoma?Pruritus Cases From the Field: Real-World Perspectives on Managing CKD-aP
https://practicaldermatology.com/programs/cme/pruritus-cases-from-the-field-real-world-perspectives-on-managing-ckd-ap/14969/Did you know that many patients on dialysis suffer from itch, or pruritus? Hear patients describe their experiences with a new FDA-approved therapy.Why We Should Be PRO Patients With CKD-Associated Pruritus
https://practicaldermatology.com/programs/cme/why-we-should-be-pro-patients-with-ckd-associated-pruritus/14968/Our experts offer tips to effectively use Patient-Reported Outcome Measures (PROMs) in clinical practice to improve health outcomes in patients with CKD-aP.Holding Court in Melanoma: Choosing the Optimal Adjuvant Treatment Approach for Stage III BRAF-Mutant Melanoma
https://practicaldermatology.com/programs/cme/holding-court-in-melanoma-choosing-the-optimal-adjuvant-treatment-approach-for-stage-iii-braf-mutant-melanoma/15435/How can we choose the best adjuvant treatment strategy for melanoma patients with BRAF-activating tumors? Don’t miss this series.DermWireTV: Vtama Approved; Monkey Pox; AbbVie Scholarship; LRP Pride in Dermatology
https://practicaldermatology.com/topics/psoriasis/dermwiretv-vtama-approved-monkey-pox-abbvie-scholarship-lrp-pride-in-dermatology/20097/Vtama (tapinarof) cream 1% from Dermavant is approved for the treatment of psoriasis in adults. Tapinarof is an aryl hydrocarbon receptor agonist. As a public health service, VisualDx is offering pictures of monkey pox and disease information to support clinical decision-making. Forty-five scholarshGuidelines for PsO, SRT; Promising Data from Sienna
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-guidelines-for-pso-srt-promising-data-from-sienna/19551/Two new guidelines from the American Academy of Dermatology and the National Psoriasis Foundation outline best practices for treating psoriasis, with a focus on comorbidities and biologic treatment. A new retrospective study shows a cure rate above 97 percent among older patients treated with superfAltreno's Approval, Psoriasis Insights
https://practicaldermatology.com/topics/psoriasis/dermwire-tv-altreno-s-approval-psoriasis-insights--nxhineya/18236/Ortho Dermatologics' Altreno lotion is now approved for the topical treatment of acne vulgaris in patients ages 9 and up. Altreno, containing tretinoin 0.05%, will be available during the fourth quarter of this year. The FDA has accepted Ortho Dermatologics' resubmitted New Drug Application for Duob